The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database.
 
Benjamin H Lowentritt
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Dendreon; Janssen Oncology; Merck; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Blue Earth Diagnostics; Janssen Oncology; Lantheus Medical Imaging; Merck; Myovant Sciences; Pfizer
Research Funding - Blue Earth Diagnostics; Dendreon; Janssen Oncology; Myovant Sciences
 
Carmine Rossi
Consulting or Advisory Role - Janssen Scientific Affairs (Inst)
 
Shawn Du
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Erik Muser
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Frederic Kinkead
Consulting or Advisory Role - Janssen Scientific Affairs (Inst)
 
Dexter Waters
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Patrick Lefebvre
Consulting or Advisory Role - Janssen Scientific Affairs (Inst)
 
Dominic Pilon
Consulting or Advisory Role - Janssen Scientific Affairs (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)